Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – –...
Source: marketscreener.com